Cargando…
Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
BACKGROUND: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. METHODS: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902167/ https://www.ncbi.nlm.nih.gov/pubmed/35273475 http://dx.doi.org/10.3389/fnins.2022.815556 |
_version_ | 1784664538412482560 |
---|---|
author | Alharbi, Norah Matar, Rawan Cupler, Edward Al-Hindi, Hindi Murad, Hatem Alhomud, Iftteah Monies, Dorota Alshehri, Ali Alyahya, Mossaed Meyer, Brian Bohlega, Saeed |
author_facet | Alharbi, Norah Matar, Rawan Cupler, Edward Al-Hindi, Hindi Murad, Hatem Alhomud, Iftteah Monies, Dorota Alshehri, Ali Alyahya, Mossaed Meyer, Brian Bohlega, Saeed |
author_sort | Alharbi, Norah |
collection | PubMed |
description | BACKGROUND: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. METHODS: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. RESULTS: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. CONCLUSION: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended. |
format | Online Article Text |
id | pubmed-8902167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89021672022-03-09 Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia Alharbi, Norah Matar, Rawan Cupler, Edward Al-Hindi, Hindi Murad, Hatem Alhomud, Iftteah Monies, Dorota Alshehri, Ali Alyahya, Mossaed Meyer, Brian Bohlega, Saeed Front Neurosci Neuroscience BACKGROUND: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. METHODS: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. RESULTS: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. CONCLUSION: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended. Frontiers Media S.A. 2022-02-22 /pmc/articles/PMC8902167/ /pubmed/35273475 http://dx.doi.org/10.3389/fnins.2022.815556 Text en Copyright © 2022 Alharbi, Matar, Cupler, Al-Hindi, Murad, Alhomud, Monies, Alshehri, Alyahya, Meyer and Bohlega. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Alharbi, Norah Matar, Rawan Cupler, Edward Al-Hindi, Hindi Murad, Hatem Alhomud, Iftteah Monies, Dorota Alshehri, Ali Alyahya, Mossaed Meyer, Brian Bohlega, Saeed Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia |
title | Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia |
title_full | Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia |
title_fullStr | Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia |
title_full_unstemmed | Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia |
title_short | Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia |
title_sort | clinical, neurophysiological, radiological, pathological, and genetic features of dysferlinopathy in saudi arabia |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902167/ https://www.ncbi.nlm.nih.gov/pubmed/35273475 http://dx.doi.org/10.3389/fnins.2022.815556 |
work_keys_str_mv | AT alharbinorah clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT matarrawan clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT cupleredward clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT alhindihindi clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT muradhatem clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT alhomudiftteah clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT moniesdorota clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT alshehriali clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT alyahyamossaed clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT meyerbrian clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia AT bohlegasaeed clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia |